SCHEMBL3807151

SCHEMBL3807151

CC(=O)O[C@H]1NC(=O)[C@@H]1O[Si](C)(C)C(C)(C)C

nearest known ligand 0.36

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
PREP P48147 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10585129 1.00 MAPT (0.36) MAPTHPGDPREP
SCHEMBL9358907 0.77 POLB (0.38)
SCHEMBL6695781 0.75 MAPT (0.39) MAPTHPGDPREP
SCHEMBL10402846 0.74 ELANE (0.35)
SCHEMBL10402765 0.74 ELANE (0.35)
SCHEMBL10747693 0.74 ELANE (0.35)
SCHEMBL10553544 0.74 CTSL (0.31) MAPTHPGD
SCHEMBL9313048 0.74 CTSL (0.31) MAPTHPGD
SCHEMBL5857804 0.74 CTSL (0.31) MAPTHPGD
SCHEMBL9423301 0.74 CTSL (0.31) MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114685554-A Preparation method of 4AA diastereoisomer 武汉中有药业有限公司 2022-07-01 CN disclosed
CN-114685339-A Preparation method of 4AA diastereoisomer 武汉中有药业有限公司 2022-07-01 CN disclosed
CN-114685340-A Preparation method of 4AA diastereoisomer 武汉中有药业有限公司 2022-07-01 CN disclosed
CN-103613526-A Preparation method of meropenem intermediate cyclization compound JIANGSU HANKUO BIOLOG CO LTD 2014-03-05 CN disclosed
US-8232389-B2 Method for crystallization of azetidinonecarboxylic acid KANEKA CORPORATION (JP) 2012-07-31 US disclosed
US-20100298556-A1 Method for crystallization of azetidinonecarboxylic acid KANEKA CORPORATION (JP) 2010-11-25 US disclosed
EP-2030977-A1 IMPROVED METHOD FOR CRYSTALLIZATION OF AZETIDINONECARBOXYLIC ACID Kaneka Corporation (JP) 2009-03-04 EP disclosed
EP-0502464-A1 Antibacterial condensed carbapenemes GLAXO S.p.A. (IT) 1992-09-09 EP disclosed
EP-0247378-B1 PROCESS FOR PREPARING 4-ACETOXY-3-HYDROXYETHYLAZETIDIN-2-ONE DERIVATIVES KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1990-09-19 EP disclosed
US-4914200-A REACTING PROTECTED BETA-LACTAM WITH ACETIC ANHYDRIDE IN ORGANIC SOLVENT CONTAINING WATER OR ACETIC ACID IN PRESENCE OF PYRIDINE COMPOUND AT LOW TEMPERATURE KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1990-04-03 US disclosed
EP-0247378-A1 Process for preparing 4-acetoxy-3-hydroxyethylazetidin-2-one derivatives KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1987-12-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298556-A1 Method for crystallization of azetidinonecarboxylic acid HPD, DECR2, SRD5A2 MAPT 3000/4885HPGD 1119/4885PREP 2071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.